Equity Details
Price & Market Data
Price: $22.67
Daily Change: -$0.328 / 1.45%
Daily Range: $22.34 - $23.10
Market Cap: $2,569,631,744
Daily Volume: 1,236,295
Performance Metrics
1 Week: -1.82%
1 Month: 0.31%
3 Months: -8.99%
6 Months: 48.88%
1 Year: 185.8%
YTD: 5.63%
About Immunome, Inc. (IMNM)
A complete market overview for Immunome, Inc. (IMNM). The stock is at 22.67, with a daily change of -$0.328 / 1.45%. Market cap: 2,569,631,744. Delve into its YTD and 3-month performance.
Company Details
Employees: 177
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.